Updated Results from Phase 2 SPiReL Study Evaluating IMV’s DPX-Survivac as Combination Therapy in Patients with r/r DLBCL to be Presented at 61st American Society of Hematology (ASH) Annual Meeting

87.5% of evaluable subjects exhibited clinical benefit, including 2 complete responses and 3 partial responses All patients tested were positive

Read more
Show Buttons
Hide Buttons